The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia
Menée dans divers contextes économiques (américain, européen et autres pays développés), cette étude compare le rapport coût-efficacité d'inhibiteurs de tyrosine kinase seconde génération et de l'imatinib, en traitement de première ligne chez des patients atteints d'une leucémie myéloïde chronique en phase chronique
20 years have passed since the first clinical use of tyrosine kinase inhibitors (TKIs) and in that time, chronic myeloid leukaemia has changed from a fatal illness to a chronic one. Life expectancy among patients with chronic myeloid leukaemia is nearly identical to that of the general population. Issues now facing patients are maintaining quality of life with minimisation of side-effects, as well as cost-effectiveness strategies, both for patients and society. Treatment-free remission addresses both these issues. However, only 20% of patients on TKIs will successfully achieve treatment-free remission, therefore although it is an important goal of treatment for chronic myeloid leukaemia, the medical community still needs to focus on the majority of patients who remain on TKIs